Carmustine
DB00262
Approved Indication
For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
1
Targets
0
Resistance Mutations
0
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Carmustine causes cross-links in DNA and RNA, leading to the inhibition of DNA synthesis, RNA production and RNA translation (protein synthesis). Carmustine also binds to and modifies (carbamoylates) glutathione reductase. This leads to cell death.
Details
DrugBank ID
DB00262 ↗
Approval Date
1996-09-24
Molecular Weight
214.05 g/mol
Drug Class
Other
ATC Codes
L01AD01
Synonyms
BCNU, Bicnu (tn), bis-chloroethylnitrosourea
PubChem
CID: 2578 ↗
ChEMBL
CHEMBL513 ↗
SMILES
ClCCNC(=O)N(CCCl)N=O
ADMET Profile
Computing properties…